Health
AstraZeneca Pauses £200 Million Investment in UK Headquarters
A pedestrian passes the construction site of AstraZeneca’s facility at the Cambridge Biomedical Campus (CBC) in Cambridge, UK.
Photographer: Jason Alden/BloombergAstraZeneca Plc said it’s pausing a planned £200 million ($235 million) expansion of its headquarters in the UK, a further blow to the nation’s life sciences ambitions after Merck & Co. scrapped a major research hub there.
Astra was set to add another 1,000 employees to its operations in Cambridge, with a new facility to be built adjacent to its global R&D Discovery Centre. The company did not give a reason for the pause.